Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LMY004
MIFTS: 59

Leiomyosarcoma

Categories: Cancer diseases, Muscle diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Leiomyosarcoma

About this section

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 77 54 60 56 6 45 15 17 74
Leiomyosarcomas 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 35


External Ids:

Disease Ontology 12 DOID:1967
MeSH 45 D007890
NCIt 51 C3158
SNOMED-CT 69 51549004
MESH via Orphanet 46 D007890
ICD10 via Orphanet 35 C49.9
UMLS via Orphanet 75 C0023269
Orphanet 60 ORPHA64720
UMLS 74 C0023269
Sources

Summaries for Leiomyosarcoma

About this section
NIH Rare Diseases : 54 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to myxoid leiomyosarcoma and cutaneous leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include uterus, liver and smooth muscle, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 77 Leiomyosarcoma, also referred to as LMS, is a malignant (cancerous) smooth muscle tumor. A benign tumor... more...

Sources

Related Diseases for Leiomyosarcoma

About this section

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
# Related Disease Score Top Affiliating Genes
1 myxoid leiomyosarcoma 34.3 ACTC1 PGR
2 cutaneous leiomyosarcoma 33.8 ACTC1 DES FH
3 small intestine leiomyosarcoma 33.6 IGF2 KIT
4 epithelioid leiomyosarcoma 33.5 ACTC1 DES ENO2 SERPINA3 VIM
5 gastric leiomyosarcoma 32.9 ENO2 IGF2 KIT PDGFRA
6 uterine carcinosarcoma 30.5 KIT PGR TP53
7 bizarre leiomyoma 30.5 ACTC1 PGR
8 adenocarcinoma 30.3 CDK4 KIT PDGFRB TP53
9 smooth muscle tumor 30.3 ACTC1 DES KIT PGR VIM
10 sarcoma 30.3 CDK4 KIT MDM2 TP53 VIM WT1
11 sarcoma, synovial 30.3 DES KIT MDM2 VIM
12 fibrous histiocytoma 30.3 ACTC1 DES S100B SERPINA3 VIM
13 carcinosarcoma 30.2 ACTC1 DES KIT PGR TP53 VIM
14 liposarcoma 30.1 CDK4 DES MB MDM2 TP53 VIM
15 mesenchymoma 30.1 DES MB MDM2
16 neurofibroma 30.1 KIT PDGFRA S100B
17 giant cell tumor 30.0 ACTC1 DES SERPINA3 VIM
18 histiocytoma 30.0 KIT MB MDM2 SERPINA3 TP53
19 gastrointestinal stromal tumor 30.0 ACTC1 DES ENO2 IGF2 KIT PDGFRA
20 spindle cell sarcoma 30.0 ACTC1 DES MDM2 S100B VIM
21 endosalpingiosis 30.0 PGR WT1
22 leiomyoma 30.0 ACTC1 DES FH IGF2 KIT PGR
23 benign breast phyllodes tumor 30.0 KIT PGR VIM
24 malignant giant cell tumor 30.0 ACTC1 S100B TP53
25 hypereosinophilic syndrome 30.0 KIT PDGFRA PDGFRB
26 myxoid liposarcoma 29.9 CDK4 MDM2 TP53
27 teratoma 29.9 ACTC1 ENO2 KIT TP53
28 syringocystadenoma papilliferum 29.9 ACTC1 DES S100B VIM
29 angiomyoma 29.9 ENO2 KIT MB
30 dedifferentiated liposarcoma 29.8 ACTC1 CDK4 DES MDM2 TP53
31 endometrial cancer 29.8 CDK4 KIT MDM2 PGR TP53
32 glomus tumor 29.7 ACTC1 DES ENO2 TP53 VIM
33 malignant fibroxanthoma 29.7 ACTC1 CDK4 DES MDM2 S100B SERPINA3
34 diffuse peritoneal leiomyomatosis 29.7 KIT PGR WT1
35 desmoid tumor 29.7 KIT PDGFRA PDGFRB
36 epulis 29.6 DES ENO2 PGR VIM
37 endometrial stromal sarcoma 29.6 ACTC1 DES KIT MB PDGFRB PGR
38 neurilemmoma 29.5 DES ENO2 KIT PDGFRA S100B VIM
39 pleomorphic adenoma 29.5 ACTC1 MDM2 S100B TP53 VIM
40 cutaneous fibrous histiocytoma 29.5 ACTC1 DES S100B SERPINA3 VIM
41 embryonal rhabdomyosarcoma 29.3 DES IGF2 MB MYOG
42 renal cell carcinoma, nonpapillary 29.2 FH KIT PDGFRB S100A1 VIM WT1
43 uterine sarcoma 29.1 DES KIT MB MDM2 PDGFRB WT1
44 spinal meningioma 29.1 ENO2 IGF2 PGR
45 glioblastoma 29.1 CDK4 MDM2 PDGFRA PDGFRB TP53
46 glioblastoma multiforme 29.1 CDK4 MDM2 PDGFRA PDGFRB TP53
47 meningioma, familial 28.9 ENO2 IGF2 PGR TP53
48 malignant mesenchymoma 28.9 CDK4 DES KIT MB MDM2 MYOG
49 malignant peripheral nerve sheath tumor 28.7 ACTC1 CDK4 KIT MDM2 PDGFRA S100A1
50 dermatofibrosarcoma protuberans 28.4 ACTC1 DES KIT PDGFRA PDGFRB S100B

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma
Sources

Symptoms & Phenotypes for Leiomyosarcoma

About this section

MGI Mouse Phenotypes related to Leiomyosarcoma:

47 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 ACTC1 CDK4 DES ENO2 FH IGF2
2 behavior/neurological MP:0005386 10.44 CDK4 DES ENO2 IGF2 KIT MDM2
3 cardiovascular system MP:0005385 10.44 ACTC1 CDK4 DES IGF2 KIT MB
4 homeostasis/metabolism MP:0005376 10.44 ACTC1 CDK4 DES FH IGF2 KIT
5 growth/size/body region MP:0005378 10.35 ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
6 embryo MP:0005380 10.34 CDK4 IGF2 KIT MB MDM2 MYOG
7 muscle MP:0005369 10.34 ACTC1 CAPN6 CDK4 DES IGF2 KIT
8 mortality/aging MP:0010768 10.33 ACTC1 CDK4 DES FH IGF2 KIT
9 hematopoietic system MP:0005397 10.26 CDK4 IGF2 KIT MB MDM2 PDGFRA
10 endocrine/exocrine gland MP:0005379 10.2 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
11 integument MP:0010771 10.19 CDK4 IGF2 KIT MDM2 MYOG PDGFRA
12 craniofacial MP:0005382 10.18 CAPN6 ENO2 IGF2 KIT MDM2 PDGFRA
13 digestive/alimentary MP:0005381 10.17 CAPN6 CDK4 IGF2 KIT MDM2 PDGFRA
14 normal MP:0002873 10.1 ACTC1 CDK4 KIT MDM2 MYOG PDGFRA
15 limbs/digits/tail MP:0005371 10.02 IGF2 KIT MDM2 PDGFRA PDGFRB PGR
16 no phenotypic analysis MP:0003012 9.97 IGF2 KIT MDM2 MYOG PDGFRA PGR
17 neoplasm MP:0002006 9.95 CDK4 KIT MDM2 PDGFRA PGR TP53
18 renal/urinary system MP:0005367 9.81 CDK4 FH IGF2 KIT MDM2 PDGFRA
19 pigmentation MP:0001186 9.65 CDK4 KIT MDM2 PDGFRA TP53
20 reproductive system MP:0005389 9.65 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
21 respiratory system MP:0005388 9.32 ENO2 IGF2 KIT MB MYOG PDGFRA
Sources

Drugs & Therapeutics for Leiomyosarcoma

About this section

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 6857599 5310940 9887054 43805
2 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 1,Not Applicable
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
7
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
9
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
10
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
13
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
14
Carboplatin Approved Phase 3,Phase 2 41575-94-4 38904 10339178 498142
15
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
16
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
17
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Ondansetron Approved Phase 3 99614-02-5 4595
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
22
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
23
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
24 Olaratumab Approved, Investigational Phase 3,Phase 2,Phase 1 1024603-93-7
25
Histamine Approved, Investigational Phase 3 51-45-6 774
26
Cyproheptadine Approved Phase 3 129-03-3 2913
27
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
28 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
30 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
32
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
40 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
42 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
43 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
44 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
45 Etoposide phosphate Phase 3,Phase 2
46 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1
49 Anesthetics, General Phase 3
50 Analgesics Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
5 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
6 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
12 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
13 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Completed NCT00423618 Phase 3
15 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
18 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
19 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
20 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
21 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
22 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
23 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
24 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
25 Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Not yet recruiting NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
26 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
27 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
28 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
29 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
30 Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Unknown status NCT01442662 Phase 2 pazopanib + gemcitabine
31 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
32 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
33 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
34 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
35 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
36 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
37 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
38 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
39 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Completed NCT02428192 Phase 2
40 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
41 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
42 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
43 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
44 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
45 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
46 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
47 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
48 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
49 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
50 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Sources

Genetic Tests for Leiomyosarcoma

About this section
Sources

Anatomical Context for Leiomyosarcoma

About this section

MalaCards organs/tissues related to Leiomyosarcoma:

42
Uterus, Liver, Smooth Muscle, Lung, Breast, Bone, Colon
Sources

Publications for Leiomyosarcoma

About this section

Articles related to Leiomyosarcoma:

(show top 50) (show all 3397)
# Title Authors Year
1
PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. ( 30829727 )
2019
2
Ileal leiomyosarcoma presenting with intussusception. ( 30800281 )
2019
3
Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study. ( 30498966 )
2019
4
A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). ( 30519622 )
2019
5
Irreversible electroporation in a case of pancreatic leiomyosarcoma: a novel weapon versus a rare malignancy? ( 30611280 )
2019
6
A Case of Mediastinal Leiomyosarcoma Demonstrated on FDG PET/CT Imaging. ( 30624267 )
2019
7
MRI screening for uterine leiomyosarcoma. ( 30637854 )
2019
8
Clinicopathological features of primary thyroid leiomyosarcoma without Epstein-Barr virus infection: A case report. ( 30655765 )
2019
9
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. ( 30660363 )
2019
10
Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. ( 30683135 )
2019
11
Soft tissue leiomyosarcoma-diagnostics, management, and prognosis: Data of the registry cancer of the center of Tunisia. ( 30719261 )
2019
12
A case of subcutaneous leiomyosarcoma of the scrotum presenting as a slowly growing mass in a 36-year-old male: A case report and literature review. ( 30719409 )
2019
13
Treatment of leiomyosarcoma in a tiger (Panthera tigris) with stereotactic radiotherapy. ( 30746806 )
2019
14
Synchronous metastatic leiomyosarcoma and primer invasive ductal carcinoma tumors in the same breast: Mammography, ultrasonography, and magnetic resonance imaging findings. ( 30761666 )
2019
15
Preoperative intravascular ultrasonographic evaluation of leiomyosarcoma of the inferior vena cava: A case report. ( 30762237 )
2019
16
Polytetrafluoroethylene is a safe and effective interposition conduit for caval reconstruction after resection of primary leiomyosarcoma of the inferior vena cava. ( 30769055 )
2019
17
Leiomyosarcoma Manifesting With Bowel Obstruction. ( 30772310 )
2019
18
Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. ( 30793095 )
2019
19
Leiomyosarcoma of the Right Gonadal Vein: Review of the Approach and Prognostic in a Rare Case. ( 30805242 )
2019
20
A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. ( 30807865 )
2019
21
Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma. ( 30811297 )
2019
22
Unusual presentation of metastatic leiomyosarcoma-right forearm swelling. ( 30834106 )
2019
23
Primary leiomyosarcoma of the thyroid gland with prior malignancy and radiotherapy: A case report and review of literature. ( 30842958 )
2019
24
Primary hepatic leiomyosarcoma successfully treated by transcatheter arterial chemoembolization: A case report. ( 30842965 )
2019
25
Laparoscopic pancreaticoduodenectomy for remnant pancreatic recurrence after laparoscopic distal pancreatectomy and hepatectomy for greater omentum leiomyosarcoma. ( 30843350 )
2019
26
Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report. ( 30847179 )
2019
27
Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. ( 30867634 )
2019
28
Primary leiomyosarcoma of the colon: a case report and review of the literature. ( 30879400 )
2019
29
Autotransplantation of the Liver for Ex Vivo Resection of Intrahepatic Caval Leiomyosarcoma: A Case Report. ( 30880647 )
2019
30
Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage. ( 30881199 )
2019
31
Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy. ( 30887661 )
2019
32
A large soft tissue mass with multiple cysts-Primary leiomyosarcoma of the seminal vesicle. ( 30887718 )
2019
33
Imaging findings of ovarian leiomyosarcoma with histopathologic correlations. ( 30898403 )
2019
34
Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy. ( 30898939 )
2019
35
Two Modest Proposals: Thoughts from the Fibroid/Leiomyosarcoma Controversies. ( 30904485 )
2019
36
Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas. ( 30724615 )
2019
37
Laparoscopic surgery to treat leiomyosarcomas of the sigmoid colon:a case report and literature review. ( 30756192 )
2019
38
Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. ( 30804704 )
2019
39
Recurrence of Primary Vascular Leiomyosarcoma Five Years after Initial Diagnosis in the Lower Extremity. ( 29971175 )
2018
40
Primary leiomyosarcoma in the colon: A case report. ( 29443772 )
2018
41
Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )
2018
42
Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. ( 29379638 )
2018
43
Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report. ( 29387393 )
2018
44
Delayed diagnosis of dermal leiomyosarcoma mimicking keloid scar. ( 29374640 )
2018
45
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
46
Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma. ( 29399140 )
2018
47
Leiomyosarcoma of the great saphenous vein (vena saphena magna) with granular cell change: Report of a superficial neoplasm. ( 29068077 )
2018
48
Options for Adjuvant Therapy for Uterine Leiomyosarcoma. ( 29417238 )
2018
49
Role of bevacizumab in uterine leiomyosarcoma. ( 29759566 )
2018
50
Partial cystectomy for a primary locally advanced leiomyosarcoma of the bladder: a case report and review of the literature. ( 29744079 )
2018
Sources

Variations for Leiomyosarcoma

About this section

ClinVar genetic disease variations for Leiomyosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
2 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 687)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6987318 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 0
2 COSM212945 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 0
3 COSM6986268 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 0
4 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 0
5 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 17:7675185-7675185 0
6 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 17:7674872-7674872 0
7 COSM10704 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 0
8 COSM44327 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.518T>C p.V173A 17:7675094-7675094 0
9 COSM43615 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>C p.R158P 17:7675139-7675139 0
10 COSM307332 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.976G>A p.E326K 17:7673552-7673552 0
11 COSM44057 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.517G>C p.V173L 17:7675095-7675095 0
12 COSM1640842 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 0
13 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 17:7675157-7675157 0
14 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 17:7675218-7675218 0
15 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 0
16 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 17:7674945-7674945 0
17 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
18 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 17:7674900-7674900 0
19 COSM10735 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.638G>A p.R213Q 17:7674893-7674893 0
20 COSM10667 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.646G>A p.V216M 17:7674885-7674885 0
21 COSM44610 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.97-2A>T p.? 17:7676274-7676274 0
22 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 17:7674251-7674251 0
23 COSM43965 TP53 soft tissue,smooth muscle,leiomyoma,NS c.734G>C p.G245A 17:7674229-7674229 0
24 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 17:7675211-7675211 0
25 COSM43753 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.560-1G>A p.? 17:7674972-7674972 0
26 COSM45135 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.673-1G>T p.? 17:7674291-7674291 0
27 COSM13745 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.994-1G>C p.? 17:7670716-7670716 0
28 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 0
29 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 0
30 COSM44537 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.595G>T p.G199* 17:7674936-7674936 0
31 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 17:7675139-7675139 0
32 COSM11073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 0
33 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 17:7675161-7675161 0
34 COSM10663 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.916C>T p.R306* 17:7673704-7673704 0
35 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 17:7675077-7675077 0
36 COSM43989 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.596G>A p.G199E 17:7674935-7674935 0
37 COSM44415 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.711G>C p.M237I 17:7674252-7674252 0
38 COSM21585 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-2A>T p.? 17:7675238-7675238 0
39 COSM44190 TP53 soft tissue,liver,sarcoma,NS c.359A>T p.K120M 17:7676010-7676010 0
40 COSM10654 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.637C>T p.R213* 17:7674894-7674894 0
41 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 17:7674199-7674199 0
42 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 17:7673764-7673764 0
43 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 17:7674250-7674250 0
44 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 17:7673812-7673812 0
45 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 17:7673573-7673573 0
46 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 17:7674255-7674255 0
47 COSM3849376 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.753C>G p.I251M 17:7674210-7674210 0
48 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 17:7674884-7674884 0
49 COSM43596 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>A p.D281N 17:7673779-7673779 0
50 COSM44076 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.655C>T p.P219S 17:7674876-7674876 0

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma
Sources

Expression for Leiomyosarcoma

About this section
Search GEO for disease gene expression data for Leiomyosarcoma.
Sources

Pathways for Leiomyosarcoma

About this section

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 65
Show member pathways
 13.76 CAPN6 CDK4 DES IGF2 KIT MDM2
2
Phospholipase-C Pathway 65
Show member pathways
 12.94 IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3
PI3K-Akt signaling pathway 38
Show member pathways
 12.75 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
4
Endometrial cancer 38
Show member pathways
 12.73 CDK4 KIT MDM2 PDGFRA PDGFRB TP53
5
MAPK signaling pathway 1 38
12.65 IGF2 KIT PDGFRA PDGFRB TP53
6
Gastric cancer 38
Show member pathways
 12.64 CDK4 IGF2 KIT PGR TP53
7
Glioma 38
Show member pathways
 12.6 CDK4 MDM2 PDGFRA PDGFRB TP53
8
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.6 KIT MDM2 PDGFRA PDGFRB TP53
9
MicroRNAs in cancer 38
12.35 MDM2 PDGFRA PDGFRB TP53 VIM
10
Pathways in cancer 38
12.28 CDK4 FH IGF2 KIT MDM2 PDGFRA
11
Human T-cell leukemia virus 1 infection 38
12.27 CDK4 PDGFRA PDGFRB TP53
12
Apoptosis Pathway 73
Show member pathways
 12.22 CAPN6 MDM2 PDGFRA PDGFRB TP53
13
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.13 IGF2 KIT PDGFRA PDGFRB TP53
14
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.02 CDK4 MDM2 PDGFRA PDGFRB TP53
15
AKT Signaling Pathway 68
11.87 CDK4 MDM2 PDGFRA PDGFRB TP53
16
Retinoblastoma (RB) in Cancer 1
11.75 CDK4 MDM2 TP53
17
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.7 PDGFRA S100B VIM
18
Imatinib Pathway, Pharmacokinetics/Pharmacodynamics 62
Show member pathways
 11.68 KIT PDGFRA PDGFRB
19
Bladder cancer 38 1
11.65 CDK4 MDM2 TP53
20
Striated Muscle Contraction 1 67
11.63 ACTC1 DES VIM
21
Integrated Cancer Pathway 1
11.39 CDK4 MDM2 TP53
22
Central carbon metabolism in cancer 38
11.37 KIT PDGFRA PDGFRB TP53
23
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.36 CDK4 MDM2 TP53
24
Cardiac Progenitor Differentiation 1
11.18 ACTC1 IGF2 KIT PDGFRA
25
Glioblastoma Multiforme 65
11.15 CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
26
Oncogene Induced Senescence 67
11.14 CDK4 MDM2 TP53
27
G-protein signaling_Rap2B regulation pathway 23
10.87 DES IGF2 KIT PDGFRA PDGFRB VIM
Sources

GO Terms for Leiomyosarcoma

About this section

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.83 IGF2 KIT PDGFRA PDGFRB
2 positive regulation of gene expression GO:0010628 9.8 ACTC1 KIT MDM2 TP53 VIM WT1
3 positive regulation of MAPK cascade GO:0043410 9.78 IGF2 KIT PDGFRA PDGFRB
4 cell chemotaxis GO:0060326 9.75 KIT PDGFRA PDGFRB
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 KIT PDGFRA PDGFRB
6 positive regulation of fibroblast proliferation GO:0048146 9.71 CDK4 PDGFRA PDGFRB
7 muscle filament sliding GO:0030049 9.67 ACTC1 DES VIM
8 metanephric mesenchyme development GO:0072075 9.56 PDGFRB WT1
9 retina vasculature development in camera-type eye GO:0061298 9.55 PDGFRA PDGFRB
10 negative regulation of apoptotic process GO:0043066 9.55 ACTC1 MDM2 PDGFRB TP53 WT1
11 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.54 KIT PDGFRA PDGFRB
12 metanephric S-shaped body morphogenesis GO:0072284 9.51 PDGFRB WT1
13 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
14 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRA PDGFRB
15 cardiac myofibril assembly GO:0055003 9.43 ACTC1 PDGFRA PDGFRB
16 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA PDGFRB
17 positive regulation of cell proliferation GO:0008284 9.17 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
18 positive regulation of phospholipase C activity GO:0010863 9.13 KIT PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 KIT PDGFRA PDGFRB
2 identical protein binding GO:0042802 9.5 DES MDM2 PGR S100A1 S100B TP53
3 platelet-derived growth factor binding GO:0048407 9.37 PDGFRA PDGFRB
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KIT PDGFRA PDGFRB
5 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRA PDGFRB
6 protein binding GO:0005515 10.19 CDK4 DES ENO2 FH IGF2 KIT
Sources

Sources for Leiomyosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....